论文部分内容阅读
目的观察甘精胰岛素联合阿卡波糖和(或)二甲双胍治疗肥胖T2DM临床疗效。方法 32例肥胖T2DM患者,在注射预混Ins一段时间后血糖控制不理想情况下,改用甘精胰岛素联合阿卡波糖和(或)二甲双胍,疗程3个月,观察治疗前后BP、FPG、HbA_1c、TC、TG、HDL-C、LDL-C、UA、C-P、uAER变化情况,计算HOMA-IR、HOMA-β。结果治疗后BMI、FPG、HOMA-IR低于治疗前,而C-P、HOMA-β高于治疗前(P<0.05)。结论甘精胰岛素联合阿卡波糖和(或)二甲双胍治疗肥胖T2DM,不仅成功控制血糖,且明显改善IR,治疗中无明显体重增加等不良反应。
Objective To observe the clinical effects of glargine combined with acarbose and (or) metformin in the treatment of obese T2DM. Methods 32 cases of obese T2DM patients were treated with insulin glargine plus acarbose and metformin for 3 months after the injection of premixed Ins for some time. The levels of BP, FPG, HbA_1c, TC, TG, HDL-C, LDL-C, UA, CP and uAER were calculated. HOMA-IR and HOMA-β were calculated. Results After treatment, BMI, FPG and HOMA-IR were lower than those before treatment, while C-P and HOMA-β were higher than before treatment (P <0.05). Conclusion Glargine combined with acarbose and metformin in the treatment of obese T2DM not only succeeded in controlling blood glucose, but also significantly improved IR. There was no significant adverse reactions such as weight gain during treatment.